- Home
- UL vs SNY Comparison
UL vs SNY Comparison
Compare UL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- SNY
- Stock Information
- Founded
- UL 1930
- SNY 1994
- Country
- UL United Kingdom
- SNY France
- Employees
- UL N/A
- SNY N/A
- Industry
- UL Package Goods/Cosmetics
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- UL Consumer Discretionary
- SNY Health Care
- Exchange
- UL Nasdaq
- SNY Nasdaq
- Market Cap
- UL 136.3B
- SNY 120.2B
- IPO Year
- UL N/A
- SNY N/A
- Fundamental
- Price
- UL $55.68
- SNY $50.74
- Analyst Decision
- UL Buy
- SNY Buy
- Analyst Count
- UL 5
- SNY 2
- Target Price
- UL $60.00
- SNY $57.50
- AVG Volume (30 Days)
- UL 2.5M
- SNY 2.3M
- Earning Date
- UL 02-06-2025
- SNY 01-30-2025
- Dividend Yield
- UL 3.42%
- SNY 4.01%
- EPS Growth
- UL N/A
- SNY N/A
- EPS
- UL 2.82
- SNY 4.00
- Revenue
- UL $64,601,950,064.00
- SNY $54,031,898,261.00
- Revenue This Year
- UL $2.91
- SNY $0.88
- Revenue Next Year
- UL $3.40
- SNY $6.28
- P/E Ratio
- UL $19.46
- SNY $25.09
- Revenue Growth
- UL N/A
- SNY 6.01
- 52 Week Low
- UL $46.46
- SNY $45.22
- 52 Week High
- UL $65.87
- SNY $58.97
- Technical
- Relative Strength Index (RSI)
- UL 38.68
- SNY 63.19
- Support Level
- UL $54.60
- SNY $47.88
- Resistance Level
- UL $56.43
- SNY $51.08
- Average True Range (ATR)
- UL 0.59
- SNY 0.66
- MACD
- UL -0.02
- SNY 0.29
- Stochastic Oscillator
- UL 35.25
- SNY 89.67
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.